Sarepta Narrows Revenue Guidance Amid Leadership Transition and Pipeline Progress — Sarepta Therapeutics, Inc.

Event summary

Sarepta reported $328.7 million in total net product revenue for Q2 2026, down from $611.1 million in Q2 2025 due to lower ELEVIDYS sales and decreased collaboration revenues.
Michael Severino appointed as CEO effective July 28, 2026, succeeding Doug Ingram, who will serve in an advisory capacity through the end of 2026.
FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53 seeking conversion from accelerated to traditional approval.
Narrowed FY 2026 revenue guidance to $1.2-$1.3 billion, down from the previous range of $1.2-$1.4 billion.

The big picture

Sarepta's Q2 2026 results reflect the ongoing transition in leadership and the strategic reprioritization of its pipeline. The company's focus on executing its commercial strategy, advancing its siRNA pipeline, and maintaining disciplined capital allocation comes at a time when the biotech sector is under pressure to deliver tangible clinical benefits and regulatory approvals. The narrowed revenue guidance underscores the need for Sarepta to demonstrate sustained momentum in its core Duchenne muscular dystrophy (DMD) franchise while expanding into new therapeutic areas.

What we're watching

Pipeline Progress: The pace at which Sarepta can deliver on key data readouts for DM1 and FSHD in the second half of 2026 will be critical to maintaining investor confidence.
Regulatory Headwinds: Whether the FDA's acceptance of supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53 will lead to successful conversion from accelerated to traditional approval remains uncertain.
Execution Risk: How the new leadership under Michael Severino will navigate the challenges of sustaining growth and advancing the siRNA pipeline amid a competitive landscape.